nodepositrealmoneyslots| Baiji Shenzhou BTK inhibitor Baiyueze approved for follicular lymphoma indication in China

Baiji Shenzhou announced on May 13 that its BTK inhibitor Baiyuze ® (zebutinib) has been conditionally approved for registration by the State Food and Drug Administration of China (SMPA), adding the following indications: Combined with Otuzizumab, suitable for patients who have received at least second-line systemic therapy in the pastnodepositrealmoneyslotsof adult patients with relapsed or refractory follicular lymphoma (FL).